Curretab

ANDA 85686, held by Solvay. Medroxyprogesterone Acetate.

As of Nov 15, 2026, ANDA 85686 (Curretab), held by Solvay, was first approved by FDA on Apr 28, 1978, with 3 approved supplements and 0 published complete response letters.

First approved: Apr 28, 1978
Supplements approved: 3
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below

Date	Submission	Status	Documents
Apr 28, 1978	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Curretab10MG · tablet;oral	Medroxyprogesterone Acetate	Discontinued

All 4 submissions, including labeling and manufacturing supplements


Jul 22, 1993	Supplement 64Labeling	Approved	None posted
Mar 11, 1992	Supplement 59Labeling	Approved	None posted
Jul 14, 1989	Supplement 53Labeling	Approved	None posted
Apr 28, 1978	Original application	Approved	None posted

Identifiers

Application: ANDA 85686
Drugs@FDA: Overview at FDA
Company: Solvay

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters